D. Boral Capital Reiterates “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $2.00 price objective on the stock. D. Boral Capital’s price objective would suggest a potential upside of 284.47% from the stock’s current price.

LCTX has been the topic of a number of other research reports. Maxim Group cut their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, February 11th.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $0.52 on Tuesday. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61. The stock has a market cap of $114.66 million, a P/E ratio of -4.34 and a beta of 1.21. The firm has a fifty day moving average of $0.60.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently made changes to their positions in LCTX. Squarepoint Ops LLC acquired a new position in Lineage Cell Therapeutics in the 4th quarter valued at about $46,000. Two Sigma Advisers LP grew its stake in shares of Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after purchasing an additional 65,864 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $152,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lineage Cell Therapeutics during the fourth quarter worth approximately $519,000. Finally, Deutsche Bank AG lifted its holdings in shares of Lineage Cell Therapeutics by 196.0% during the fourth quarter. Deutsche Bank AG now owns 174,702 shares of the company’s stock worth $87,000 after purchasing an additional 115,672 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.